首页> 美国卫生研究院文献>Theranostics >Stimuli-responsive nanodrug self-assembled from amphiphilic drug-inhibitor conjugate for overcoming multidrug resistance in cancer treatment
【2h】

Stimuli-responsive nanodrug self-assembled from amphiphilic drug-inhibitor conjugate for overcoming multidrug resistance in cancer treatment

机译:由两亲药物抑制剂偶联物自组装的刺激反应性纳米药物用于克服癌症治疗中的多药耐药性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Severe multidrug resistance (MDR) often develops in the process of chemotherapy for most small molecule anticancer drugs, which results in clinical chemotherapy failures.>Methods: Here, a nanodrug is constructed through the self-assembly of amphiphilic drug-inhibitor conjugates (ADIC) containing a redox-responsive linkage for reversing the multidrug resistance (MDR) in cancer treatment. Specifically, hydrophilic anticancer irinotecan (Ir) and hydrophobic P-gp protein inhibitor quinine (Qu) are linked by a redox responsive bridge for overcoming MDR of tumors.>Results: Ir-ss-Qu is able to self-assemble into nanoparticles (NPs) in water and shows the longer blood retention half-life compared with that of free Ir or Qu, which facilitates drug accumulation in tumor site. After endocytosis of Ir-ss-Qu NPs by drug-resistant tumor cells, the disulfide bond in the linkage between Ir and Qu is cleaved rapidly induced by glutathione (GSH) to release anticancer drug Ir and inhibitor Qu synchronously. The released Qu can markedly reduce the expression of P-gp in drug-resistant tumor cells and inhibits P-gp to pump Ir out of the cells. The increased concentration of intracellular Ir can effectively improve the therapeutic efficacy.>Conclusions: Such redox-responsive Ir-ss-Qu NPs, as a drug delivery system, exhibit very high cytotoxicity and the most effective inhibitory to the growth of drug-resistant breast cancer compared with that of free therapeutic agents in vitro and in vivo.
机译:大多数小分子抗癌药物的化疗过程中经常会产生严重的多药耐药性,导致临床化疗失败。>方法:在此,通过两亲药物的自组装构建了纳米药物。 -包含氧化还原反应性连接键的抗氧化剂偶联物(ADIC),用于逆转癌症治疗中的多药耐药性(MDR)。具体而言,亲水性抗癌伊立替康(Ir)和疏水性P-gp蛋白抑制剂奎宁(Qu)通过氧化还原反应桥连接,从而克服了肿瘤的MDR。>结果: Ir-ss-Qu能够自我-在水中组装成纳米颗粒(NPs),与游离Ir或Qu相比,血液保留半衰期更长,这有助于药物在肿瘤部位的蓄积。耐药肿瘤细胞对Ir-ss-Qu NPs进行内吞后,谷胱甘肽(GSH)迅速裂解Ir和Qu之间的键中的二硫键,从而同步释放抗癌药物Ir和抑制剂Qu。释放的Qu可以显着降低耐药性肿瘤细胞中P-gp的表达,并抑制P-gp将Ir泵出细胞。增加的细胞内Ir浓度可以有效提高治疗效果。>结论:这种氧化还原反应性Ir-ss-Qu NP作为药物递送系统,具有很高的细胞毒性,并且对这种药物具有最有效的抑制作用。与游离治疗剂在体外和体内的生长相比,耐药性乳腺癌的生长快。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号